Skip to main content

FDMT

Stock
Health Care
Biotechnology

Performance overview

FDMT Price
Price Chart

Forward-looking statistics

Beta
0.95
Risk
88.87%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Company info

SectorHealth Care
IndustryBiotechnology
Employees144
Market cap$1.2B

Fundamentals

Enterprise value-$125.7M
Revenue$23.0K
Revenue per employee
Profit margin0.00%
Debt to equity5.08

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.18
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth-6.1
Credit+6.1
Liquidity+0.2
Inflation-8.9
Commodities-3.5
Interest Rates-3.9

Valuation

Dividend yield0.00%
PEG Ratio-1.29
Price to sales8539.84
P/E Ratio-1.29
Enterprise Value to Revenue-5466.07
Price to book0.42

Upcoming events

Next earnings dayAugust 6, 2025
Next dividend day
Ex. dividend day

News

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.66 per share a year ago.

Zacks Investment Research (May 8, 2025)
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

On Saturday, 4D Molecular Therapeutics FDMT announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population.

Benzinga (February 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free